WithdrawnEarly Phase 1

Imaging of Solid Tumors Using DLL3 SPECT

Stopped: Sponsor funding

0Started 2026-04-30

Plain-language summary

This is a single arm, pilot trial that evaluates the ability of a novel imaging agent (111In-ABD147) to detect metastatic cancer in participants with solid tumors. 111In-ABD147 is a high affinity Delta-like ligand 3 (DLL3) antigen binding domain fused to an engineered humanized Fc to create an antibody (VHH-Fc) that is bio-conjugated with a DOTA linker-chelator to a 111In radiometal. DLL3 is expressed on a variety of tumors, particularly those with neuroendocrine features.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥ 18 years
✓. Histopathologically confirmed solid tumors in one of the following cohorts:
✓. Cohort 1 (n=15): Histologically confirmed prostate cancer, with castration resistant disease per Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria.
✓. Cohort 2 (n=15): Histologically confirmed high grade neuroendocrine tumor, with a Ki-67 over 20.
✓. Cohort 3 (n=15): Agnostic to tumor type.
✓. Metastatic disease present on conventional imaging defined as having Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable disease or multiple bone metastases.
✓. Ability to understand a written informed consent document, and the willingness to sign it.

Exclusion criteria

✕. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.
✕. Has known hypersensitivity to Chinese hamster ovary cell products.
✕. Has a history of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins.
✕. Known pregnancy.

What they're measuring

Standardized Uptake Values (SUVs)

Timeframe: 2 days

Tumor-to-background ratio (TBR)

Timeframe: 2 days

Trial details

NCT IDNCT07052760

SponsorThomas Hope

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-05-31

View on ClinicalTrials.gov More Solid Tumor Cancer trials